AB Science S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABSCF research report →
About the company
AB Science S. A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors, designed for applications in both human and animal medicine.
- CEO
- Alain Moussy
- IPO
- 2011
- Employees
- 40
- HQ
- Paris, FR
Price Chart
- Market Cap
- $78.15M
- P/E
- -36.30
- P/S
- 45.94
- P/B
- -3.29
- EV/EBITDA
- -39.44
- Div Yield
- 0.00%
- Gross Margin
- 61.33%
- Op Margin
- -103.66%
- Net Margin
- -132.62%
- ROE
- 6.99%
- ROIC
- -5.53%
- Revenue
- $1.17M · 9.47%
- Net Income
- $-1,556,416 · 80.12%
- EPS
- $-0.03 · 83.07%
- Op Income
- $-1,216,543
- FCF YoY
- -1334.94%
- 52W High
- $2.70
- 52W Low
- $1.12
- 50D MA
- $1.15
- 200D MA
- $1.31
- Beta
- 1.22
- Avg Volume
- 18
Get TickerSpark's AI analysis on ABSCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ABSCF coverage
Recent articles, reports, and earnings notes.
No research on ABSCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABSCF report →Similar companies
Peers in the same neighborhood.